Premium
Specific antagonism of adenosine‐induced bronchoconstriction in asthma by oral theophylline.
Author(s) -
Mann JS,
Holgate ST
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb02696.x
Subject(s) - bronchoconstriction , theophylline , bronchodilator , adenosine , histamine , antagonist , medicine , placebo , asthma , pharmacology , chemistry , anesthesia , endocrinology , receptor , alternative medicine , pathology
The airway response to increasing concentrations of inhaled‐adenosine and histamine after oral theophylline or matched placebo was studied in nine asthmatic subjects. Changes in airway calibre were followed as sGaw and FEV1 and concentration‐response curves constructed. Inhaled adenosine caused concentration‐related bronchoconstriction and was four‐ five times less potent than inhaled histamine. Theophylline, which achieved a mean plasma level of 15.9 and 16.6 micrograms/ml on the histamine and adenosine study days respectively, caused significant increases in FEV1 (17%) and sGaw (41‐53%) whereas placebo had no effect. Theophylline also protected the airways against histamine‐and adenosine‐induced bronchoconstriction. However theophylline had a greater protective effect against adenosine (concentration‐ratio 17.4 for FEV1 and 12.8 for sGaw) than against histamine (concentration ratio 5.6 for FEV1 and 5.4 for sGaw (P less than 0.05]. At therapeutic concentrations theophylline is a specific antagonist of the airway effects of adenosine in addition to being a bronchodilator and a functional antagonist.